Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

The isothermal nucleic acid amplification technology (inaat) market size has grown rapidly in recent years. It will grow from $3.53 billion in 2023 to $3.91 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to several key factors, including the increased demand for infectious disease diagnostics, the expansion of point-of-care testing (POCT) solutions, efforts to control tuberculosis, advancements in molecular diagnostics, and the growing presence of these technologies in emerging markets. These factors collectively contributed to the growth in this period.

The isothermal nucleic acid amplification technology (inaat) market size is expected to see rapid growth in the next few years. It will grow to $6.39 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The anticipated growth in the forecast period can be attributed to various key factors, including increased focus on pandemic preparedness, addressing the challenges of antimicrobial resistance, growing importance of environmental monitoring, advancements in oncology diagnostics, and the impact of global health initiatives. Notable trends expected to shape this period include the adoption of multiplexing techniques, miniaturization of technologies, digital detection methods, the development of sample-to-answer systems, and the integration of gene editing technologies, reflecting the evolving landscape of isothermal nucleic acid amplification technology.

The rising incidence of Infectious and Chronic Diseases is a significant driver behind the expansion of the Isothermal Nucleic Acid Amplification Technology (INAAT) market. Diseases such as H. influenzae, S. pneumonia (respiratory tract infections), N. gonorrhoeae, C. trachomatis (genital infections), and TB are on the increase, demanding diagnostic solutions like isothermal nucleic acid amplification technology (INAAT). According to the World Health Organization (WHO), an estimated 10 million people contract tuberculosis every year, resulting in 1.5 million deaths. The growing prevalence of infectious and chronic diseases is a key factor fueling the expansion of the isothermal nucleic acid amplification technology market.

The primary product types associated with isothermal nucleic acid amplification technology include instruments and reagents. Reagents are substances or compounds introduced into a system to induce a chemical reaction or to determine whether a reaction has occurred. Various technologies, such as NASBA and HAD, are used in this context and are typically applied in areas like blood screening, infectious disease diagnostics, and cancer-related analyses. The end users of this technology encompass hospitals, reference laboratories, and other institutions.

The isothermal nucleic acid amplification technology (INAAT) market research report is one of a series of new reports that provides isothermal nucleic acid amplification technology (INAAT) market statistics, including isothermal nucleic acid amplification technology (INAAT) industry global market size, regional shares, competitors with a isothermal nucleic acid amplification technology (INAAT) market share, detailed isothermal nucleic acid amplification technology (INAAT) market segments, market trends and opportunities, and any further data you may need to thrive in the isothermal nucleic acid amplification technology (INAAT) industry. This isothermal nucleic acid amplification technology (INAAT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Government initiatives aimed at healthcare research and development are poised to significantly drive the growth of the isothermal nucleic acid amplification technology market in the future. These initiatives involve specific actions, programs, or policies launched by government entities to tackle various healthcare issues, including supporting isothermal nucleic acid amplification technology. In 2022, the UK's Department of Health and Social Care (DHSC) announced a £260 million ($270.65 million) funding commitment to foster healthcare research and manufacturing. This funding, established by the Department for Business, Energy and Industrial Strategy (BEIS) and DHSC, aims to facilitate NHS-led health research, privacy-preserving platforms for diagnostics and treatments, and bolster life sciences manufacturing in the UK. Hence, government initiatives focused on healthcare research and development are propelling the isothermal nucleic acid amplification technology market.

The market for isothermal nucleic acid amplification technology faces strict regulations imposed by stringent policies governing the operations, approvals, and manufacturing standards of this sector. These regulatory policies act as a deterrent for companies looking to invest in new product research and development or expand into new markets. For instance, the US Food and Drug Administration (USFDA) mandates a multi-laboratory validation process for loop-mediated isothermal amplification, which takes twice as long as the review process by the European regulatory body. Prolonged regulatory procedures delay further exploration of device safety and efficacy studies, impacting vendor operating cycles and subsequently hindering market growth.

Nanostructures are increasingly integrated into in vitro diagnostics and in vitro rapid diagnostic tests (RDTs) to enhance existing tests' effectiveness and develop innovative diagnostic approaches for point-of-care applications. Nanostructures and nanotechnology employ nanoparticles to improve drug actions in treatments. Nanotechnology entails designing, characterizing, producing, and applying devices, structures, and systems by precisely manipulating size and shape at the nanometer scale. Several RDTs have been created for syphilis diagnosis, such as AccuBioTech (Accu-Tell Rapid Syphilis Test), Alere, Inc. (Alere Determine), Alere/Standard Diagnostics (SD Syphilis 3.0), The Tulip Group/Qualpro (Syphicheck - WB), Cypress Diagnostics (Syphilis Rapid Test), and Omega Diagnostics (Visitect Syphilis). These RDTs enable patients to receive diagnoses at the point of care (POC).

Major companies operating in the isothermal nucleic acid amplification technology market are developing innovative solutions like the QIAstat-Dx syndromic testing solution to gain a competitive advantage. The QIAstat-Dx system is an integrated, multiplexed molecular testing platform that combines sample preparation, nucleic acid amplification, and detection within a single cartridge. For instance, in April 2023, Qiagen, a Netherlands-based company specializing in isothermal nucleic acid amplification technology (INAAT) for various applications, introduced the QIAstat-Dx syndromic testing solution. This system provides Ct (cycle threshold) values and access to amplification curves, allowing clinicians to monitor amplification progress and make well-informed diagnostic decisions.

In July 2021, Sapphiros, a KKR-backed platform focused on advancing the next generation of diagnostic technologies, acquired Biocrucible Ltd. for an undisclosed sum. This acquisition aimed to establish leading consumer molecular diagnostics in the market. Biocrucible Ltd., a UK-based biotechnology company, is known for accelerating and enhancing biochemical kinetics through its Molten TagsTM technology.

Major companies operating in the isothermal nucleic acid amplification technology (inaat) market include Alere Inc., biomeriux SA, Qiagen NV, Becton, Dickson & Company, Hologica Inc., Lucigen Corporation, Quidel Corporation, New England Biolabs Inc., NuGen, Ustar Biotechnologies Ltd., Thermo Fisher Scientific Inc., BioHelix Corporation, Meridian Bioscience Inc., Novartis AG, Sharp Corporation, Sony Corporation, Panasonic Holdings Corporation, Toshiba Corporation, Rohm Co Ltd., PhilipsHologic-Gen-Probe, BetaLED, Avago Technologies Ltd., Grifols SA, Abbott Laboratories, Jena Bioscience GmbH, Atila Biosystems Incorporated, TwistDx Ltd., LGC Ltd., DiaSorin SpA, OptiGene Limited

North America was the largest region in the isothermal nucleic acid amplification technology (INAAT) market in 2023. Western Europe was the second largest region in the isothermal nucleic acid amplification technology (INAAT) market. The regions covered in the isothermal nucleic acid amplification technology (inaat) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the isothermal nucleic acid amplification technology (inaat) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The isothermal nucleic acid amplification technology (INAAT) market includes revenues earned by reaction systems and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.